Leonhardt Ventures Announces Provisional Patent Application on Bioelectric Modulation of FOXO3, AMPK, and mTOR Pathways for Healthspan Longevity and Regenerative Medicine

May 6, 2026

HUNTINGTON BEACH, Calif. — May 5, 2026 — Leonhardt Ventures LLC announced today a new provisional patent application covering systems and methods for bioelectric modulation of the FOXO3, AMPK, and mTOR signaling pathways for applications in healthspan longevity, regenerative medicine, performance optimization, and disease modulation. The technology has been licensed to Lionheart Health, Inc. for commercialization and clinical development.

The provisional patent application, invented by Howard J. Leonhardt, covers wearable, implantable, and external bioelectric stimulation systems designed to dynamically regulate major longevity-associated pathways involved in mitochondrial function, autophagy, stem cell preservation, tissue regeneration, muscle maintenance, metabolic optimization, cognitive performance, vascular function, and immune resilience.

The technology platform combines frequency-specific bioelectric stimulation with adaptive waveform control, AI-driven personalization, biomarker-guided optimization, and optional integration with regenerative biologics including peptides, stem cells, exosomes, hydrogels, gene therapies, red light therapy, PEMF, and neuromuscular stimulation systems.

“FOXO3, AMPK, and mTOR are among the most important master regulators of aging, regeneration, metabolism, and tissue preservation,” stated Howard J. Leonhardt, Executive Chairman and CEO of Leonhardt Ventures and Executive Chairman and Co-CEO of Lionheart Health. “Our goal is to develop non-invasive and implantable bioelectric systems capable of safely optimizing these pathways dynamically and potentially improving healthspan, resilience, regeneration, and quality of life.”

The patent pending application in process further expands the Leonhardt portfolio of bioelectric protein expression and regenerative medicine intellectual property.

Key Targeted Applications To Be Covered by the Patent Application

Longevity & Healthspan

  • Healthy aging optimization
  • Frailty reduction
  • Biological age optimization
  • Cellular resilience enhancement
  • Mitochondrial optimization
  • Autophagy enhancement
  • Circadian rhythm synchronization

Muscle, Bone & Performance

  • Sarcopenia reduction
  • Muscle preservation during aging
  • Athletic performance optimization
  • Recovery enhancement
  • Bone density support
  • Osteoporosis applications
  • Mobility and gait enhancement

Brain & Cognitive Health

  • Cognitive performance enhancement
  • Neuroprotection
  • Memory support
  • Mood optimization
  • Brain regeneration support
  • Neurodegenerative disease applications

Metabolic & Cardiovascular Applications

  • Metabolic syndrome applications
  • Glucose regulation support
  • Weight management
  • Cardiovascular support
  • Vascular regeneration
  • Blood pressure optimization
  • Kidney protection and regeneration support

Regenerative Medicine Applications

  • Stem cell enhancement
  • Stem cell homing optimization
  • Exosome enhancement
  • Wound healing
  • Organ regeneration
  • Tissue engineering support
  • Bioelectric-enhanced regenerative biologics

Aesthetic & Wellness Applications

  • Skin rejuvenation
  • Hair regeneration
  • Sexual wellness
  • Energy and vitality enhancement
  • Wellness optimization programs

Platform Technologies Included

  • Wearable stimulation systems
  • Implantable stimulation systems
  • AI-driven adaptive waveform systems
  • Closed-loop biomarker feedback systems
  • Whole-body stimulation suits
  • Bioelectric-enhanced peptide delivery systems
  • Circadian synchronized stimulation systems
  • Combination regenerative therapy platforms
Lionheart Health plans to evaluate the technology across multiple wellness, regenerative medicine, aesthetics, and healthspan optimization programs including BodStim™, Brain Band™, OrthoStim™, SkinStim™, HairCell™, ErectiStim TM, HairCell TM, Second Brain TM, EyeCell TM, BladderCell TM, KidneyCell TM, BioLeonhardt TM, Lionheart Octopus TM, RegenaLung TM, VascuStim TM, InStim TM, PressureStim™, and future Klotho-enhanced regenerative therapy platforms.

For additional information visit:
www.lionhearthealthstim.com
www.lionheartlongevity.com

Forward-Looking Statements and Disclaimers

This press release contains forward-looking statements regarding investigational technologies, potential therapeutic applications, research initiatives, intellectual property development, and future commercialization activities. These statements are subject to risks, uncertainties, regulatory review, and ongoing research outcomes. No claims are made regarding cure, prevention, or treatment of disease unless specifically cleared by applicable regulatory authorities.  Patent filings may not meet requirements or may be delayed. Patents filed may not be issued. Additional data needs to be gathered. Company may not raise resources needed to fully develop this technology or prosecute patent issuance with USPTO.
Howard J. Leonhardt
Executive Chairman & CEO
Lionheart Health, Inc.
Leonhardt Ventures LLC
4440 Von Karman, Ste 100
Newport Beach, CA 92660

Related Posts: